Evidence map›Paper›PMID 28620704›Full record

Observational studyGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2017

Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the RANIDEX study.

Irini Chatziralli, George Theodossiadis, Stamatina A Kabanarou, Efstratios Parikakis, Tina Xirou, Panagiotis Mitropoulos, Panagiotis Theodossiadis

Abstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 3 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 3 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Observational
  7. Review
  8. Article
  9. Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the Ranidex study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2017
    Article
  10. Ranibizumab versus dexamethasone implant for central retinal vein occlusion: special remarks of the RANIDEX study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 1 country.

Irini Chatziralli2nd Department of Ophthalmology, "Attikon" Hospital, National and Kapodistrian University of Athens, Athens, Greece. eirchat@yahoo.gr.
George Theodossiadis2nd Department of Ophthalmology, Henry Dunant Hospital, Athens, Greece.
Stamatina A KabanarouMedical Retina Department, Korgialeneio Benakeio, Red Cross Hospital, Athens, Greece.
Efstratios Parikakis2nd Department of Ophthalmology, Ophthalmiatrion Athinon, Athens, Greece.
Tina XirouMedical Retina Department, Korgialeneio Benakeio, Red Cross Hospital, Athens, Greece.
Panagiotis Mitropoulos2nd Department of Ophthalmology, Ophthalmiatrion Athinon, Athens, Greece.
Panagiotis Theodossiadis2nd Department of Ophthalmology, "Attikon" Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Athens Eye Hospital · GRHellenic Red Cross · GRHenry Dunant Hospital · GRNational and Kapodistrian University of Athens · GRRed Cross Hospital · GRUniversity General Hospital Attikon · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare intravitreal ranibizumab and dexamethasone implant in patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).

methodsParticipants were 42 treatment naive patients with ME due to CRVO, who received either intravitreal 0.5 mg ranibizumab (n = 25) or intravitreal 0.7 mg dexamethasone implant (n = 17). The main outcomes included the mean change in best corrected visual acuity (BCVA) and central subfield thickness (CST) at month 12 compared to baseline in the two groups.

resultsAt month 12, there was no statistically significant difference in BCVA and CST change between the two groups. However, there was recurrence in ME at month 5 in the dexamethasone group.

conclusionsBoth ranibizumab and dexamethasone implant were found to be safe and effective at the 12-month follow-up in patients with ME secondary to CRVO. Since there was a recurrence in ME at month 5 in the dexamethasone group, we suggested that intravitreal injection of dexamethasone implant should be potentially administered sooner than 6 months.

Indexed as

AgedAngiogenesis InhibitorsDexamethasoneDose-Response Relationship, DrugDrug ImplantsFemaleGlucocorticoidsHumansIntravitreal InjectionsMaleMiddle AgedProspective StudiesRanibizumabRetinal Vein OcclusionTime FactorsTomography, Optical CoherenceAngiogenesis InhibitorsDexamethasoneDrug ImplantsGlucocorticoidsRanibizumabCentral retinal vein occlusionDexamethasoneInflammationRanibizumabTreatment

Identifiers

PMID28620704
OpenAlexW2624785543

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.